SCHEMBL6330463

SCHEMBL6330463

O=[N+]([O-])c1ccc(-c2nc3ccc(C(F)(F)F)cc3[nH]2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.73
MAPT P10636 5/20 0.73
RAB9A P51151 5/20 0.73
MMP2 P08253 4/20 0.73
MMP9 P14780 4/20 0.73
MMP8 P22894 4/20 0.73
MMP13 P45452 3/20 0.73
HTT P42858 3/20 0.73
CASP3 P42574 2/20 0.73
SENP8 Q96LD8 2/20 0.73
SENP7 Q9BQF6 2/20 0.73
SENP6 Q9GZR1 2/20 0.73
NPBWR1 P48145 11/20 0.70
DGAT1 O75907 4/20 0.66
KCNH2 Q12809 4/20 0.66
SMN1; SMN2 Q16637 4/20 0.63
NFKB1 P19838 2/20 0.63
NFKB2 Q00653 2/20 0.63
RELA Q04206 2/20 0.63
MEN1 O00255 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330461 0.90 NPC1 (0.61) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL30343727 0.90 NPC1 (0.61) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL30726440 0.86 RAB9A (0.75) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL27040204 0.86 RAB9A (0.75) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL5566191 0.85 NPC1 (1.00) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL3204662 0.84 RAB9A (0.75) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL20982761 0.83 NPC1 (0.97) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL6325684 0.83 NPC1 (0.79) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL20982700 0.82 NPC1 (0.94) NPC1MAPTRAB9AMMP2MMP9
SCHEMBL22439772 0.80 NPC1 (0.79) NPC1MAPTRAB9AMMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050277686-A1 Benzimidazole compounds for regulating IgE SIRCAR JAGADISH C 2005-12-15 US disclosed
US-6911462-B2 Benzimidazole compounds for regulating IgE AVANIR PHARMACEUTICALS (US) 2005-06-28 US disclosed
US-20030100582-A1 Benzimidazole compounds for regulating IgE AVANIR PHARMACEUTICALS 2003-05-29 US disclosed
US-6369091-B1 ANTIALLERGENS AVANIR PHARMACEUTICALS 2002-04-09 US disclosed
EP-1079830-A1 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE Avanir Pharmaceuticals (US) 2001-03-07 EP disclosed
WO-1999061020-A1 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE AVANIR PHARMACEUTICALS (US) 1999-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100582-A1 Benzimidazole compounds for regulating IgE FCER2, SERPINB1, BRPF3 NPC1 3329/4885MAPT 3023/4885RAB9A 4088/4885
US-20050277686-A1 Benzimidazole compounds for regulating IgE FCER2, SERPINB1, BRPF3 NPC1 3329/4885MAPT 3023/4885RAB9A 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.